ACADIA Pharmaceuticals (ACAD) 2020年年度报告「NASDAQ」.pdf

《ACADIA Pharmaceuticals (ACAD) 2020年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《ACADIA Pharmaceuticals (ACAD) 2020年年度报告「NASDAQ」.pdf（118页珍藏版）》请在三个皮匠报告上搜索。

1、2020 Annual ReportIn 2020,Acadia relocated its corporate headquarters into a LEED certifiedbuilding in San Diego,California.Acadia aspires to enable brighter moments forpatients and their loved ones.For more than 25 years we have been working at the forefront of healthcare to bring vital solutions t

2、o people who need them most.We developed and commercialized the first and only approved therapy for hallucinations anddelusions associated with Parkinsons disease psychosis.Our late-stage development efforts are focused on dementia-related psychosis,negative symptoms of schizophrenia and Rett syndro

3、me,and in early-stage clinical research we areexploring novel approaches to pain management,and cognition and neuropsychiatric symptoms in central nervous system disorders.Acadia is trailblazing breakthroughs in neuroscience to elevate lifeDear Shareholders,In 2020,we made signifi cant progress in t

4、he execution of our strategy with exceptional performancein the midst of a global pandemic.Acadia delivered a strong year with continued operational growthwhile advancing the next wave of breakthroughs in neuroscience.The signifi cant potential ofpimavanserin,combined with our innovative pipeline an

5、d purpose-driven mission,will delivermeaningful long-term growth.Continued Strong Growth for NUPLAZID(pimavanserin)We continue to build on our strong NUPLAZID foundation in Parkinsons disease psychosis,or PDP.For the full year 2020 we achieved net sales for NUPLAZID of$441.8 million.This represents

6、a 30%year-over-year increase.This growth is a result of the focused execution of our commercial team,and since launching in 2016,we have achieved consistent year-over-year growth in net sales of NUPLAZID.In June 2020,we submitted a supplemental New Drug Application(sNDA)for pimavanserin for the trea